Omeros Corporation (OMER) Stock Price

OMERStock

$18.61+339.95%52W

Market Cap$1.35B

P/E—

PEG Ratio0.81

Div yield—

Beta2.62

OMER Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)49.20%

Price vs S&P 500 (4W)46.63%

PEG Ratio0.81

VGM Score64.08

Book Value / Share (Quarterly)$0.33

P/TBV (Annual)3.46x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.32

Price vs S&P 500 (YTD)-4.50%

Gross Margin (TTM)94.07%

Net Profit Margin (TTM)566.66%

EPS (TTM)$0.94

10-Day Avg Trading Volume1.82M

EPS Excl Extra (TTM)$0.94

EPS (Annual)$-2.71

ROI (Annual)8.98%

Gross Margin (Annual)98.78%

Net Profit Margin (5Y Avg)-185.94%

Cash / Share (Quarterly)$1.88

P/E Basic Excl Extra (TTM)14.37x

ROA (Last FY)-56.66%

EBITD / Share (TTM)$-1.26

ROE (5Y Avg)111.99%

Operating Margin (TTM)-176.09%

Cash Flow / Share (Annual)$-1.62

P/B Ratio60.36x

P/B Ratio (Quarterly)16.66x

Net Income / Employee (Annual)$-897,100

EV / Revenue (TTM)155.13x

Net Interest Coverage (TTM)-4.67x

ROA (TTM)34.53%

EV / EBITDA (TTM)7.42x

EPS Incl Extra (Annual)$-2.71

Current Ratio (Annual)2.76x

Quick Ratio (Quarterly)2.91x

3-Month Avg Trading Volume1.92M

52-Week Price Return339.95%

P/E Incl Extra (TTM)14.37x

Revenue / Employee (TTM)$56,500

Tangible BV / Share (Quarterly)$2.03

P/S Ratio (Annual)16.78x

Asset Turnover (Annual)0.41x

52-Week High$19.65

Operating Margin (5Y Avg)-171.04%

EPS Excl Extra (Annual)$-2.71

CapEx CAGR (5Y)-25.33%

26-Week Price Return61.13%

Quick Ratio (Annual)2.67x

13-Week Price Return66.91%

Total Debt / Equity (Annual)5.16x

Current Ratio (Quarterly)3.03x

Enterprise Value$1.53B

Asset Turnover (TTM)0.03x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.72x

Pretax Margin (Annual)-203.39%

Cash / Share (Annual)$2.40

3-Month Return Std Dev98.04%

Gross Margin (5Y Avg)98.25%

Net Income / Employee (TTM)$492,400

ROE (Last FY)55.34%

Net Interest Coverage (Annual)1.30x

EPS Basic Excl Extra (Annual)$-2.71

P/FCF (TTM)1.38x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)21.55x

EPS Incl Extra (TTM)$0.94

Receivables Turnover (Annual)0.00x

ROI (TTM)11.65%

P/S Ratio (TTM)125.14x

Pretax Margin (5Y Avg)-197.82%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.03

Forward P/E435.20x

Price vs S&P 500 (52W)321.39%

P/E Ratio (TTM)14.37x

Year-to-Date Return8.32%

5-Day Price Return-3.67%

EPS Normalized (Annual)$-2.71

ROA (5Y Avg)-21.95%

Net Profit Margin (Annual)-187.13%

Month-to-Date Return57.18%

Cash Flow / Share (TTM)$-2.88

EBITD / Share (Annual)$-2.90

Operating Margin (Annual)-168.02%

LT Debt / Equity (Annual)4.04x

ROI (5Y Avg)-36.17%

P/E Excl Extra (TTM)14.37x

LT Debt / Equity (Quarterly)16.70x

EPS Basic Excl Extra (TTM)$0.94

P/TBV (Quarterly)3.46x

P/B Ratio (Annual)1.65x

Inventory Turnover (TTM)0.75x

Pretax Margin (TTM)518.61%

Book Value / Share (Annual)$1.36

Price vs S&P 500 (13W)64.95%

Beta2.62x

P/FCF (Annual)16.66x

Revenue / Share (TTM)$0.11

ROE (TTM)107.50%

52-Week Low$3.94

vGradeC

mGradeA

vgmGradeB

OMER Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.33	$0.10	+128.85%(+$0.43)
Q1 2026	May 13, 2026	-$0.39	$0.57	+244.92%(+$0.96)
Q4 2025	Mar 31, 2026	$2.24	$3.14	+40.18%(+$0.90)
Q3 2025	Nov 13, 2025	-$0.48	-$0.32	+32.98%(+$0.16)
Q2 2025	Aug 14, 2025	-$0.55	-$0.53	+2.51%(+$0.01)

OMER Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
OMEROmeros Corporation	C	—	A	$18.61
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company developing targeted therapies for complement-mediated diseases and immunologic disorders. The company's lead candidate, narsoplimab, is a monoclonal antibody in clinical trials for rare immune-related conditions including thrombotic microangiopathy following stem cell transplantation and immunoglobulin nephropathy. Omeros also has programs targeting cancer and additional large-market immunologic indications.